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1. Introduction 
Human T-cell Lymphotropic Viruses (HTLVs) and Simian T-cell Lymphotropic Viruses 
(STLVs) are anciently related primate T-cell leukemia viruses (PTLVs) that share molecular 
and virological features. Human T-cell Lymphotropic Virus (HTLV-1) is believed to be 
repeatedly transmitted in separate independent events from simians to humans beginning 
50,000 ± 10,000 years ago; this course has resulted in the formation of several viral subtypes 
around the world. There are four known strains of HTLV, of which HTLV-1 and HTLV-2 are 
the most prevalent worldwide. Newer HTLVs, HTLV-3 and 4 have been identified recently 
from bush meat hunters in central Africa(Matsuoka and Jeang 2007).  
HTLV-1, the first human retrovirus was discovered by two independent investigating 
groups in 1980 and 1981. A geographical clustering of leukaemias in southwestern Japan led 
to the description of a unique clinical entity termed adult T-cell leukemia (ATL), where 
Japanese investigators identified HTLV-1 as an etiologic agent of newly described ATL, and 
the U.S. investigators detected HTLV-1 retrovirus in human cell lines (Yoshida 2010).  
HTLV-1 belongs to the Deltaretrovirus genera of the Orthoretrovirinae subfamily, the first 
discovered human retrovirus, isolated in the early 1980s from peripheral blood samples of a 
patient with cutaneous T-cell lymphoma (Poiesz et al, 1980). It is the etiologic agent of two 
predominant distinct human diseases, ATL or adult T-cell leukemia lymphoma (ATLL) and 
a chronic, progressive demyelinating disorder known as HTLV-1-associated 
myelopathy/tropical spastic paraparesis (HAM/TSP)(Zanjani et al. 2010). 
The major findings that support the etiologic association of HTLV-1 are: 1) All patients with 
ATL have antibodies against HTLV-1, 2) The areas of high incidence of ATL patients 
correspond closely with those of high incidence of HTLV-1 carriers, 3) HTLV-1 immortalizes 
human T cells in vitro, 4) Monoclonal integration of HTLV-1 proviral DNA was 
demonstrated in ATL cells. Thus, HTLV-1 is the first retrovirus directly associated with 
human malignancy (Takatsuki 2005). HTLV-1 is a complex leukemogenic retrovirus with a 
single stranded positive sense RNA genome that expresses unique proteins with oncogenic 
potential. HTLV-1 can infect T cells, B cells, monocytes, dendritic cells and endothelial cells 
with equal efficiency; yet, it can transform only primary T cells (Hanon et al. 2000).  
HTLV-2 was identified in a CD8+ T cell line derived from a patient with a variant form of 
hairy T cell leukemia. Since then, HTLV-2 has not been associated with 
leukemia/lymphoma; nevertheless, it has been associated with a few sporadic cases of 
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neurological disorders and chronic encephalomyelopathy (Hjelle et al. 1992). The clinical 
symptoms presented are similar to those of HAM/TSP. The prevalence of HTLV-2-
associated myelopathy was reported to be 1% compared to 3.7% for HTLV-1 associated 
HAM/TSP in the United State. Although other neurological disorders have been reported, 
their clear association with HTLV-2 is hampered by confounding factors such as 
intravenous drug use or concomitant HIV infection. To date, HTLV-3 and HTLV-4 have not 
been associated with any known clinical conditions (Kannian 2010).  
In 1985, Gessain et al., demonstrated that 68% of patients with tropical spastic paraparesis 
(TSP) in Martinique had positive serology for HTLV-1. In 1986, a similar neurological 
condition was described in Japan and named HTLV-1 associated myelopathy (HAM). Later, 
Román and Osame (1988) concluded that they were dealing with the same disease, and the 
term HTLV associated myelopathy/tropical spastic paraparesis (HAM/TSP) came to be 
used. Since then, countless other diseases have been correlated with this infection: uveitis, 
Sjögren’s syndrome, infectious dermatitis, polymyositis, arthropathies, thyroiditis, 
polyneuropathies, lymphocytic alveolitis, cutaneous T-cell lymphoma, strongyloidiasis, 
scabies, Hansen’s disease and tuberculosis. The importance of the possible clinical 
manifestations of the HTLV virus has now become clear in several different medical 
specialties such as oncology, neurology, internal medicine, dermatology, and 
ophthalmology (Romanelli, Caramelli and Proietti 2010).  
Only HTLV-1-infected individuals develop ATL, and all ATL cells contain integrated 
HTLV-1 provirus, supporting the causal etiology of the virus for leukaemogenesis. 
Nevertheless, only a small minority of HTLV-1-infected individuals progress to ATL. 
Indeed, the cumulative risks of developing ATL among virus carriers are estimated to be 
approximately 6.6% for males and 2.1% for females (Matsuoka and Jeang 2007).  
A long period of latency from HTLV-1 infection to ATL development suggests a multistep 
process of T-lymphocyte transformation. In ATL patients, the malignant cells typically 
consist of oligoclonal or monoclonal outgrowths of CD4+ and CD25+ T lymphocytes 
carrying a complete or defective provirus of HTLV-1. Four clinical subtypes of ATL include 
acute, lymphoma, chronic and smoldering (Noula Shembade 2010). 
2. Worldwide distribution 
Approximately 15-25 million people worldwide are infected with HTLV-1. The virus is 
endemic in southwestern Japan, Africa, the Caribbean Islands and South America and is 
frequently found in Melanesia, Papua New Guinea, Solomon Islands and Australian 
aborigines. HTLV-1 is also prevalent in certain populations in the Middle East (Iran) and 
India. HTLV-2 is more prevalent among intravenous drug users (IDUs), and is endemic 
among IDUs in the USA, Europe, South America and Southeast Asia. HTLV-3 and HTLV-4 
have been identified only in African primate hunters (Kannian 2010). HTLV-1 infection is 
endemic in northeastern Iran (Khorasan province) and the prevalence of HTLV-1 infection is 
estimated to be 2-3% in the whole population and 0.78% in blood donors (Abbaszadegan et 
al. 2003; Safai et al. 1996). 
High prevalence rates in the general population are observed in the South of Japan (10%), in 
Jamaica and Trinidad and Tobago (6%). In South America (Argentina, Brazil, Colombia and 
Peru) a 2% prevalence of seropositivity was observed among blood donors. It is known that 
the prevalence of HITLV-1 in population of blood donors represents an underestimation of 
prevalence in the general population. In absolute terms, Brazil may have the largest number 
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of seropositive people in the world. In non-endemic areas, certain groups should be 
considered as at risk, such as immigrants from endemic areas, the sexual partners and 
descendents of people known to be infected, sex professionals and drug users(Romanelli, 
Caramelli and Proietti 2010).  
HTLV-1 carriers are mostly asymptomatic in their life spans. The lifetime risks of 
developing ATL and HAM/TSP are about 2.5 to 5% and 0.3 to 2%, respectively (Silva et al. 
2007). Among HTLV-1 infected individuals in Japan, a small proportion of carriers (6% for 
males and 2% for females) develop ATL.  The majority of HTLV-1 carriers do not develop 
HTLV-1-associated diseases. The latency period from the initial infection until onset of ATL 
is about 60 years in Japan and 40 years in Jamaica. These determinations indicate a multistep 
leukemogenic mechanism in the generation of ATL. 
3. Genomic structure of HTLV-1 
HTLV-1 virions are complex type C particles, spherical, enveloped and 100–110 nm in 
diameter. The inner membrane of the virion envelope is lined by the viral matrix protein 
(MA). This structure encloses the viral capsid (CA), which carries two identical strands of 
the genomic RNA as well as functional protease (Pro), integrase (IN), and reverse 
transcriptase (RT) enzymes. A newly synthesized viral particle attaches to the target cell 
receptor through the viral envelope (Env) and enters via fusion, which is followed by the 
uncoating of the capsid and the release of its contents into the cell cytoplasm. The viral 
genome consists of a linear, positive sense, ssRNA held together by hydrogen bonds. Each 
monomer has about 9032 nucleotides. The 3’ terminal viral genome is polyadenylated and 
its 5’- terminal is capped. Each unit is associated with a specific molecule of tRNA that is 
base paired to a region, primer binding site, near the 5’ end of the RNA. Proviral forms are 
flanked at both termini by long terminal repeats (LTRs) of 754 nucleotides. The genomic 
structure encodes structural and enzymatic proteins: gag, pol, env, reverse transcriptase, 
protease, and integrase. In addition, HTLV-1 has a region at the 3’ end of the virus, called 
pX, which encodes four partially overlapping reading frames (ORFs). These ORFs code for 
regulatory proteins which impact the expression and replication of the virus (Figure 1) 
(Boxus and Willems 2009).  
The viral RNA is reverse transcribed into double stranded DNA by the RT. This double 
stranded DNA is then transported to the nucleus and becomes integrated into the host 
chromosome forming the provirus. The provirus contains the promoter and enhancer 
elements for transcription initiation in the long terminal repeats (LTR); the polyadenylation 
signal for plus strand transcription are located in the 3'LTR (Kannian 2010). 
The initial round of HTLV-1 transcription is dependent on cellular factors. The complex 
retroviral genome codes for the structural proteins Gag (capsid, nucleocapsid, and matrix), 
Pro, polymerase (Pol) and Env from unspliced/singly spliced mRNAs. Alternatively spliced 
mRNA transcripts encode regulatory and accessory proteins. The two regulatory genes rex 
and tax are encoded by open reading frames (ORF) III and IV, respectively, and share a 
common doubly spliced transcript. Tax is the transactivator gene, which increases the rate of 
viral LTR-mediated transcription and modulates the transcription of numerous cellular 
genes involved in cell proliferation and differentiation, cell cycle control and DNA repair. 
Tax has displayed oncogenic potential in several experimental systems and is essential for 
HTLV-1 and HTLV-2-mediated transformation of primary human T cells. Rex acts post-
transcriptionally by preferentially binding, stabilizing exporting intron-containing viral 
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Fig. 1. HTLV-1 genome structure and gene product 
mRNAs from the nucleus to the cytoplasm. The accessory genes, p12/p8 encoded by ORF I 
and p30/p13 encoded by ORF II is not necessary in standard immortalization assays in 
culture. However, these genes are essential for initiation of viral infection and the 
establishment of persistence in animal models. P8 is a proteolytic cleavage product of the 
p12 parent molecule, whereas the p13 polypeptide, comprised of the carboxy terminus of 
p30, is expressed from a distinct mRNA. These accessory proteins may also play a role in 
gene regulation and contribute to the productive infection of quiescent T lymphocytes in 
vitro. The minus strand of the proviral genome encodes several isoforms (generated from 
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unspliced and spliced mRNAs) of the HTLV-1 basic leucine zipper factor (HBZ). HBZ 
interacts with cellular factors JunB, c-Jun, JunD, cAMP response element binding (CREB) 
and CREB binding protein (CBP)/p300to modulate both viral and cellular gene 
transcription. HBZ also plays a crucial role in T cell proliferation. Although research data 
indicate that Tax, among all the viral proteins, is the viral oncoprotein, but emerging data 
suggests a supporting role for HBZ in the oncogenic process (Kannian 2010).  
4. Transmission 
HTLV-1 can infect various cell types, including T-lymphocytes, B-lymphocytes, monocytes, 
dendritic cells (DC) and fibroblasts. Glucose transporter 1 (GLUT-1) is ubiquitously 
expressed cell surface receptor targeted by HTLV-1 (Manel et al. 2003). Other cell surface 
receptors such as neuropilin 1 (NRP1) and surface heparan sulfate proteoglycans (HSPGs) 
have been reported to be target of HTLV-1 and are required for efficient entry (Boxus and 
Willems 2009). There is also evidence for cell-type specific receptors since a recent study has 
reported that HTLV-1 enters DCs by binding to the receptor DC-SIGN (Noula Shembade 
2010.). However, the HTLV-1 provirus is mainly detected in CD4-positive lymphocytes, 
with about 10% in CD8-positive T-lymphocytes. This situation possibly arises because of 
Tax transformation of CD4-positive T-lymphocytes in vivo causing enhanced proliferation 
and suppressed apoptosis. In HTLV-1-infected individuals, no virions are detected in the 
serum. In addition, the infectivity of free virions is very poor compared with that of infected 
cells suggesting that HTLV-1 spreads through cell-to-cell transmission, rather than by free 
virions.  In vitro analyses of HTLV-1 infected cells revealed that HTLV-1-infected cells form 
"virological synapses" with uninfected cells. The viral proteins Gag and Env, viral RNA and 
microtubules are accumulated as an infected cell is in contact with a target cell, and the viral 
complex subsequently transfers into the target cell. HTLV-1 also spreads in a cell- to-cell 
manner via such virological synapses in vivo (Igakura et al. 2003).  
In either route, HTLV-1-infected cells are essential for transmission. This was supported by 
the findings that fresh frozen plasma from carriers did not cause transmission and freeze-
thawing of breast milk reduced vertical transmission (Matsuoka 2005). 
Transplacental transmission is also suspected. Cellular blood products are the main source 
of transfusion- associated HTLV transmission, whereas fresh frozen plasma, cryoprecipitate, 
or coagulation factor concentrates appear not to cause infection (Abbaszadegan et al. 2003). 
The efficiency of virus transmission is from males to females during sexually active years 
causing a higher seroprevalence of about more than twice in females. The HTLV-1 
infection tends to be more within family members and three to four times greater than its 
rate in general population. It is proposed that repeated close contact and shared 
environment could be significant in HTLV-1 transmission (Rafatpanah et al. 2006). Viral 
antigens expressed by infected cell are quickly targeted by cytotoxic T cells; hence the 
viral load is maintained predominantly by cells harboring silent provirus spread by 
mitotic transmission. HTLV-1 transmission by free virions is very inefficient, at least in T 
cells, however, recent studies indicate that cell-free HTLV-1 virions are highly infectious 
for DCs (Noula Shembade 2010). 
4.1 Transmission of HTLV-1 occurs through three main routes 
HTLV-1 is mainly transmitted via three routes: 1) mother- to-infant transmission, mainly 
through breast feeding; 2) sexual transmission, mainly from male-to- female; and 3) 
parenteral transmission (blood transfusion or intravenous drug use). 
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Mother to child: One of the main modes of HTLV-1 transmition from mother to child is by 
breast feeding. Studies in Japan showed that the prevalence of HTLV-1 infection in children 
of carrier mothers was significantly higher (21%) than in children in the general population 
(1%). More than 85% of infected mothers had infected their children. The length of breast-
feeding affects the risk of HTLV-1 transmission. The duration of breast-feeding affects the 
risk of HTLV-1 transmission. HTLV-1 antigen in cord blood lymphocytes of babies born to 
healthy carriers raised a possibility to consider intrauterine transmission as an alternative 
pathway. However, the HTLV-1 provirus in the cord blood circulation is derived from 
migrated maternal cells that are not a part of blood circulation of the baby. Thus, 
intrauterine transmission could not be a major pathway of transmission.  
Only ~3%–4% of children become infected if they are not breast-fed or are breast- fed for 
<6 months, and the transmission risk increases with the duration of breast-feeding. The 
cumulative risk of infection in children who are regularly breast-fed is ~20%. 
Furthermore, the transmission risk increases with the amount of provirus in breast milk. 
Breast milk proviral levels also correlate with proviral levels in maternal peripheral blood 
mononuclear cells (PBMCs) and with antibody titers. It is therefore not surprising that the 
transmission risk correlates with proviral and antibody levels in maternal peripheral 
blood. However, this is contradictory to the fact that the majority of children who are 
breastfed for long periods do not become infected. HIV can also be transmitted by breast-
feeding, however, it is more commonly transmitted in utero or perinatally, As with 
HTLV-1, transmission occurs in proportion to the duration of breast-feeding, and the risk 
increases when mothers have high HIV provirus levels in breast milk, which are also 
directly correlated with peripheral blood provirus levels. Mother- to-child in utero and 
perinatal HIV transmission was more likely when children were more concordant with 
their mothers in HLA class I type. Children with HLA class I type A*02 (later reported to 
be the A2 supertype) have a decreased risk of early infection. HLA class I type variability 
is not associated with HIV transmission via breast-feeding, whereas, with HTLV-1, 
vertical transmission almost always occurs via breast-feeding. However, unlike HIV, 
HTLV-1 is transmitted primarily by cell- to-cell contact rather than by free virus. We 
reasoned that factors affecting cellular immunity might be more important for the vertical 
transmission of HTLV-1 than for HIV (Biggar et al. 2006). 
Transmission rates are 16% for children born to infected mothers, 27% for children nursed 
by infected mothers for more than three months and 5% for children nursed by infected 
mothers for less than three months (Ureta-Vidal et al. 1999). It is Interesting that HTLV is 
transmitted to about 13% of bottle-fed children from their infected mother suggesting a 
different route than breast-feeding. The infants seroconvert within 1-3 years of age (Ureta-
Vidal et al. 1999). The infants seroconvert within 1-3 years of age (Ureta-Vidal et al. 1999). 
Sexual: HTLV-1 can also be transmitted through sexual contact. Heterosexual transmission 
is able to introduce HTLV-1 infection into previously uninfected groups. Transmission from 
man to woman is more frequent (60%) than woman to man (0.4%). Like HIV, HTLV-1 can be 
transmitted through homosexual activity. Predisposing factors associated with sexual 
transmission include the presence of genital ulcers, high viral loads and high antibody titers 
in the donor (Kaplan et al. 1996).  Sexual transmission is a more common mode in non-drug 
user sexual partners of IDUs than parenteral transmission. Among IDUs, blood and blood 
products are the most significant source of infection (Roucoux and Murphy 2004).   
Blood transfusion: is the third mode of HTLV-1 transmission. The proviral DNA in donor’s 
blood lymphocytes acts as an infectious agent. The probability of seroconversion in a recipient 
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of contaminated blood is about 44%. Thus, it is essential to have an efficient blood screening 
system for HTLV-1 in endemic areas to limit the HTLV-1 transmission. Whole blood 
components, platelets and packed red blood cells, but not fresh frozen plasma, are the sources 
of virus transmission. White blood cells are reservoirs of HTLV-1. The probability of 
transmission of HTLV-1 decreases, if infected units of blood are stored for more than one week 
HTLV-1. Approximately 12% of HTLV infections occur by blood transfusion. Unlike HIV-1, 
whole cell transfusion is required for transmission of the virus, with a seroconversion rate of 
approximately 50%. The development of HAM/TSP has been noted as early as six months 
after transfusion of an individual with infected blood. In 1988, concerns about transmission of 
HTLV through blood components led to mandatory blood donor screening for HTLV 
resulting in a significant decrease in transmission via this mode. Cell-free infection with 
HTLV-1 is very inefficient; and efficient transmission depends on cell-to-cell transfer through 
direct cell contact, polarization of the microtubule-organizing center (MTOC), which is 
triggered by Tax, and the formation of a virological synapse, which allows the entry of viral 
particles, viral proteins and genomic RNA into fresh target cells. Similar to HIV-1 infection, 
dendritic cells (DCs) have been demonstrated to play a biphasic role in cell-to-cell transmission 
of HTLV-1. DCs can capture and transfer the virions to fresh T cells in a trans fashion or 
transmit de novo synthesized virions upon infection to fresh T cells in a cis fashion (Kannian 
2010). Transmission via organ transplantation has been described and is associated with 
rapidly progressing HAM/TSP, possibly because of the immunosuppression that transplant 
patients undergo (Romanelli, Caramelli and Proietti 2010). 
Contaminated needles from Drug addicts: HTLV-1 can also be transmitted by sharing of 
needles among drug addicts (Rafatpanah et al. 2006). In the United States, HTLV infection 
of intravenous drug users (IVDUs) was first reported from Queens, New York, and was 
mainly attributed to HTLV-II (Robert-Guroff et al. 1986). Subsequently, others have 
reported prevalence rates of HTLV antibody among IVDUs ranging from 0.4% to 24.0% 
(Lee et al. 1990). 
5. Diagnosis 
HTLV-1 is usually detected by carrying out laboratory tests because of clinical suspicion, 
screening at the blood bank or due to concerns by family members of HTLV-1 positive 
patients. The antibodies can be detected by enzyme-linked immunosorbent assay (ELISA). 
ELISA kits have high sensitivity and low specificity; thus, it may not be a reliable screening 
tool. Therefore, positive ELISA results should be confirmed by western blot analysis and or 
polymerase chain reaction (PCR) (Andrade et al. 2010). 
For the diagnosis of HTLV-1/2 infection, the first immunoassays used HTLV-1 whole-viral 
lysate as the only antigen. Then, assays were based on recombinant and/or synthetic 
peptide antigens only or in combination with viral lysates. Furthermore, HTLV-2 specific 
antigens were included, which improved the sensitivity for detection of HTLV- 2 antibodies. 
At present, the initial diagnosis of HTLV-1/2 infection is based mainly on screening for 
antibodies by ELISA. Even the lack of Food and Drug Administration (FDA) licensure for 
HTLV-1/2 Western blot (WB) assay, it is generally applied to all repeatedly reactive samples 
for further confirmation of HTLV-1/2 infection (CDC, 1988). The WB assay reduces the 
number of false positive transmembrane results thereby increasing the specificity for 
serological confirmation of HTLV-1/2. This assay contains viral lysates and recombinant 
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proteins. MTA-1 is a unique HTLV-1 envelope recombinant protein (rgp46-I), K-55 is a 
unique HTLV-2 envelope recombinant protein (rgp46-II), and GD21 is a common yet 
specific HTLV-1 and HTLV-2 epitope recombinant envelope protein. An HTLV-1 positive 
sample was considered when there were bands for the gag proteins p19 and p24, and the 
env proteins GD21 and rgp46-I; HTLV-2 positive if p24, GD21, and rgp46-II bands were 
present; an indeterminate sample when there were specific bands for the virus that did not 
meet the HTLV-1/2 positivity criteria, and a negative result for those samples that did not 
exhibit any specific band. In some cases, however, it is necessary to perform a 
complementary assay such as a nested-polymerase chain reaction (nested-PCR) in order to 
confirm true HTLV-1/2 infection and to obtain a conclusive diagnosis. When WB is used for 
confirmation, a significant proportion of the samples reports indeterminate results, ranging 
from0.02% in non-endemic areas to 50% in endemic ones , although it has been observed 
that indeterminate samples could result in true HTLV-1/2 infection, even in non-endemic 
areas. Several studies have shown that most low-risk HTLV-seroindeterminate and 
asymptomatic individuals are negative for HTLV-1/2 infection after testing with a highly 
sensitive nested-PCR. It is known that the use of highly efficient screening assays may 
reduce significantly false reactive results, diminishing the amount of samples further 
submitted to WB and/or nested-PCR analysis for confirmation. One of the strategies 
proposed to reduce the number of samples requiring confirmatory testing is the use of a 
dual ELISA algorithm (Yoshida 2010). 
A pitfall in ELISA-based immunoassay may exist in HTLV-1 detection due to truncated 
MTA-1 envelope glycoprotein. This report describes experiments designed to determine 
whether some discrepancies between ELISA and PCR results could be due to truncation of 
immunodominant epitopes using immunoassay method. Recombinant envelope 
glycoprotein is used in production of diagnostic enzyme-linked immunosorbent assay 
(ELISA) kit. There are some reports that a significant percentage of Iranian HTLV-1 infected 
patients showed no seroreactivity with MTA-1 peptide, while HTLV-1 had been confirmed 
by PCR detection methods or ELISA kits containing a cocktail of HTLV-1 specific peptides. 
Some discrepancies between ELISA and PCR results could be due to truncation of 
immunodominant epitopes using immunoassay method. This is because of an insertion of a 
cytosine in position 271 causing a stop codon in the MTA-1 protein translation. SDS-PAGE 
analysis also failed to reveal the presence of the desired protein. Subjects with a mutant 
HTLV-1 env gene were shown to be seronegative using ELISA, but positive with PCR 
(Abbaszadegan et al. 2008).  
Three diagnostic criteria for ATL have been defined. The first is the presence of 
morphologically proven lymphoid malignancy with T-cell surface antigens (typically CD4+, 
CD25+). These abnormal T lymphocytes have hyperlobulated nuclei in acute ATL and are 
known as “flower cells.” On the other hand, in the indolent types of ATL, smoldering and 
chronic types, the abnormality of the nuclear shape is generally milder than that in the acute 
form of the disease. The second criteria is the presence of antibodies to HTLV-1 in the sera, 
and the third is the demonstration of monoclonal integration of HTLV-1 provirus in tumor 
cells by Southern blotting (Yasunaga and Matsuoka 2007). 
6. HTLV-1 and the host immune system  
HTLV-1 is a complex retrovirus that may have been transmitted to humans from monkeys 
more than ten thousands years ago. The human host has several immune mechanisms that 
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eliminate foreign pathogens, and like other successful pathogens, HTLV-1 must have 
strategies for escaping the host immune response. 
Like HIV, HTLV-1 mainly infects CD4 T cells, which are the central regulators of the 
acquired immune response. To establish persistent infection, HTLV-1 perturbs the 
regulation of CD4 T cells, sometimes leading to diseases such as ATL or chronic 
inflammatory diseases such as HAM/TSP, uveitis, arthritis, and alveolitis. Since the 
discovery of HTLV-1, extensive studies have been performed using various experimental 
approaches to elucidate the exact pathogenesis of this virus. However, the nature of HTLV-1 
pathogenesis still remains elusive. This problem is a serious obstacle to establishing effective 
therapies for HTLV-1 associated diseases. Precise insight into HTLV-1 mediated 
pathogenesis requires careful consideration of the host cells and the effect HTLV-1 has on 
them. A better understanding of the interactions between HTLV-1 and the host immune 
system should provide additional clues to effective therapies for HTLV-1- associated 
diseases (Satou and Matsuoka 2010). 
The host immune system, especially the cellular response, against HTLV-1 exerts critical 
control over virus replication and the proliferation of infected cells. CTLs against the virus 
have been extensively studied, and Tax protein was found to be the dominant antigen 
recognized by CTLs in vivo. HTLV-1-specific CD8-positive CTLs are abundant and 
chronically activated. The paradox is that the frequency of Tax-specific CTLs is much higher 
in HAM/TSP patients than in carriers. Since the provirus load is higher in HAM/TSP 
patients, this finding suggests that the CTLs in HAM/TSP cannot control the number of 
infected cells. One explanation for this is that the CTLs in HAM/TSP patients show less 
efficient cytolytic activity toward infected cells, whereas CTLs in carriers can suppress the 
proliferation of infected cells. Hence, the gene expression profiles of circulating CD4+ and 
CD8+ lymphocytes were compared between carriers with high and low provirus loads. The 
results revealed that CD8+ lymphocytes from individuals with a low HTLV-1 provirus load 
show higher expressions of genes associated with cytolytic activities or antigen recognition 
than those from carriers with a high provirus load. Thus, CD8+ T-lymphocytes in 
individuals with a low provirus load successfully control the number of HTLV-1-infected 
cells due to their higher CTL activities. Thus, the major determinant of the provirus load is 
thought to be the CTL response to HTLV-1. As mentioned above, the provirus load is 
considered to be controlled by host factors. Considering that the cellular immune responses 
are critically implicated in the control of HTLV-1 infection, human leukocyte antigen (HLA) 
should be a candidate for such a host genetic factor. From analyses of HAM/TSP patients 
and asymptomatic carriers, HLA-A02, and Cw08 are independently associated with a lower 
provirus load and a lower risk of HAM/TSP. In addition, polymorphisms of other genes 
including TNF-ǂ, SDF-1, HLA- B54, HLA-DRB-10101 and IL-15 are also associated with the 
provirus load, however with a lower significance than with HLA-A02, and Cw08. Regarding 
the onset of ATL, only a polymorphism of TNF- ǂ gene was reported to show an association. 
However, familial clustering of ATL cases is a well-known phenomenon, strongly 
suggesting that genetic factors are implicated in the onset of ATL. Spontaneous remission is 
more frequently observed in patients with ATL than those with other hematological 
malignancies. Usually, this phenomenon is associated with infectious diseases, suggesting 
that immune activation of the host enhances the immune response against ATL cells. If the 
immune response against HTLV-1 is implicated in spontaneous remission, this suggests the 
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possibility of immunotherapy for ATL patients by the induction of an immune response to 
HTLV-1, for example via antigen-stimulated dendritic cells. Immunodeficiency in ATL 
patients is pronounced, and results in frequent opportunistic infections by various 
pathogens, including Pneumocystis carinii, cytomegalovirus, fungus, Strongyloides and 
bacteria, due to the inevitable impairment of the T-cell functions. To a lesser extent, 
impaired cell-mediated immunity has also been demonstrated in HTLV-1 carriers. Such 
immunodeficiency in the carrier state may be associated with the leukemogenesis of ATL by 
allowing the proliferation of HTLV-1-infected cells. A prospective study of HTLV-1- 
infected individuals found that carriers who later develop ATL have a higher anti-HTLV-1 
antibody and a low anti-Tax antibody level for up to 10 years preceding their diagnosis. This 
finding indicates that HTLV-1 carriers with a higher anti-HTLV-1 titer, which is roughly 
correlated with the HTLV-1 provirus load and a lower anti-Tax reactivity, may be at the 
greatest risk of developing ATL. The anti-HTLV-1 antibody and soluble IL-2 receptor (sIL-
2R) levels are correlated with the HTLV-1 provirus load, and a high antibody titer and high 
sIL-2R level are risk factors for developing ATL among carriers. Taken together, these 
findings suggest that a higher proliferation of HTLV-1-infected cells and a low immune 
response against Tax may be associated with the onset of ATL. Given these findings, 
potentiation of CTLs against Tax via a vaccine strategy may be useful for preventing the 
onset of ATL. EBV-associated lymphomas frequently develop in individuals with an 
immunodeficient state associated with transplantation or AIDS. This has also been reported 
in an ATL patient. Does such an immunodeficient state influence the onset of ATL? Among 
24 patients with post- transplantation lymphoproliferative disorders (PT-LPDs) after renal 
transplantation in Japan, 5 cases of ATL have been reported. Considering that most PT-
LPDs are of B- cell origin in Western countries, this frequency of ATL in Japan is quite high. 
Although the high HTLV-1 seroprevalence is due to blood transfusion during hemodialysis, 
the immunodeficient state during renal transplantation apparently promotes the onset of 
ATL. In addition, when experimental allogeneic transplantation was performed to 12 rhesus 
monkeys and immunosuppressive agents (cyclosporine, prednisolone or lymphocyte-
specific monoclonal antibodies) were administered to prevent rejection, 4 of the 7 monkeys 
that died during the experiment showed PT-LPDs. Importantly, the STLV pro- virus was 
detected in all PT-LPD samples. These observations emphasize that transplantation into 
HTLV-1- infected individuals or from HTLV-1 positive donors require special attention. 
Although the mechanism of immunodeficiency remains unknown, some previous reports 
have provided important clues. One mechanism for immunodeficiency is that HTLV-1 
infects CD8-positive T-lymphocytes, which may impair their functions. Indeed, the immune 
response against Tax via HTLV-1-infected CD8-positive T-cells renders these cells 
susceptible to fratricide mediated by autologous HTLV-1-specific CD8-positive T-
lymphocytes. Fratricide among virus-specific CTLs could impair the immune control of 
HTLV-1. Another mechanism for immunodeficiency is based on the observation that the 
number of naive T-cells decreases in individuals infected with HTLV-1 via decreased 
thymopoiesis [48]. In addition, CD4+ and CD25+ T-lymphocytes are classified as 
immunoregulatory T-cells that control the host immune system. Regulatory T-cells suppress 
the immune reaction via the expression of immunoregulatory molecules on their surfaces. 
The FOXP3 gene has been identified as a master gene that controls gene expressions specific 
to regulatory T-cells. FOXP3 gene transcription can be detected in some ATL cases (10/17; 
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59%). Such ATL cells are thought to suppress the immune response via expression of 
immunoregulatory molecules on their surfaces, and production of immunosuppressive 
cytokines (Matsuoka 2005). 
7. Mechanism of oncogenesis by HTLV 1 
In 1977, Takatsuki et al. reported ATL as a distinct clinical entity. This disease is 
characterized by its aggressive clinical course, infiltrations into skin, liver, gastrointestinal 
tract and lung, hypercalcemia and the presence of leukemic cells with multilobulated nuclei, 
flower cell (Figure 2). The linkage between ATL and HTLV-1 was proven by Hinuma et al., 
who demonstrated the presence of an antibody against HTLV-1 in patient sera. Thereafter, 
Seiki et al. determined the whole sequence of HTLV-1 and revealed the presence of a unique 
region, designated pX. The pX region encodes several accessory genes, which control viral 
replication and the proliferation of infected cells (Matsuoka 2005). 
 
 
Fig. 2. Typical "flower cell", Morphological findings of typical ATL cells, leukemic cells with 
multilobulated nuclei was Shawn.  
Several molecular biologic studies have reported that various cellular dysfunctions 
induced by viral genes (eg, tax and HBZ), genetic and epigenetic alterations, and the host 
immune system may be involved in the leukemogenesis of ATL. Clinical and 
epidemiologic studies have also reported a variety of possible risk factors for ATL, 
including vertical transmission of HTLV-1 infection, male gender, a long latent period, 
increased leukocyte counts or abnormal lymphocyte counts, and higher levels of anti–
HTLV-1 antibody titers and soluble interleukin-2 receptor. However, there are no clear 
determinants that separate those who develop ATL from those who remain healthy 
carriers. Recently, HTLV-1 proviral load levels have been evaluated as important 
predictors of development of ATL and HAM/TSP. Some cross-sectional studies showed 
that HTLV-1 proviral load levels were higher in ATL and HAM/TSP compared with 
asymptomatic HTLV-1 carriers. In conclusion, the cohort study of 1218 asymptomatic 
HTLV-1 carriers provided detailed distributions for HTLV-1 proviral loads regarding the 
host-specific characteristics and the associations with the development of ATL. A higher 
proviral load levels (especially > 4 copies/100 PBMCs), advanced age, family history of 
ATL, and having the first opportunity to learn of HTLV-1 infection during treatment of 
other diseases are independent risk factors for progression from carrier status to ATL. 
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Further large-scale epidemiologic studies are needed to clearly identify the determinants 
of ATL for early detection and rapid cure for HTLV-1–associated diseases(Silva et al. 
2007). Genetic and immunological factors in the host are the principal determinants of the 
emergence of associated diseases(Romanelli, Caramelli and Proietti 2010). 
7.1 Etiology of ATL 
The most important aspect of the new retroviral isolation was not just novelty but an 
etiology for a human leukemia. However, etiological proof for a human disease is generally 
not easy unless an animal model is available. The most critical question thereafter was 
whether ‘close association of HTLV-1 with ATL’ reflects its causative role or whether the 
virus was just a passenger. The nature of provirus integration of the retroviruses provided a 
critical tool for the discrimination. The retroviral genomes are generally reverse-transcribed 
into provirus DNA, and the proviral genomes are integrated into host cell DNA at random 
sites. Since a tumor originates from unlimited expansion of a single malignant cell, the site 
for the proviral integration into tumor cells would be uniform in individuals if the retroviral 
infection plays a causative role; but if the virus fortuitously infects leukemic cells, then the 
integration sites would be random. Southern blot analysis of patients’ leukemic cell DNA 
clearly indicated clonal integration in each patient revealing two distinct bands with cellular 
flanking sequences. This finding clearly supported the virus playing a causative role in ATL. 
Virtually all ATL cases were clonally infected leukemic cells; therefore, the conclusion for a 
‘causative role’ became generally accepted. As controls, the sites for the integration in viral 
carriers are random except only in a few cases which show clonal integration with higher 
viral burden (Yoshida 2005). 
7.2  Pathogenesis of HTLV-1 infection 
ATL cells are derived from activated helper T-lymphocytes, which play central roles in the 
immune system by elaborating cytokines and expressing immunoregulatory molecules. 
ATL cells are known to retain such features and this cytokine production or surface 
molecule expression may modify the pathogenesis. ATL is well known to infiltrate various 
organs and tissues, such as the skin, lungs, liver, gastrointestinal tract, central nervous 
system and bone (Takatsuki 1995). This infiltrative tendency of leukemic cells is possibly 
attributable to the expressions of various surface molecules, such as chemokine receptors 
and adhesion molecules. Skin-homing memory T-cells uniformly expresses CCR4, and its 
ligands are thymus and activation-regulated chemokine (TARC) and macrophage- derived 
chemokine (MDC). CCR4 is expressed on most ATL cells. In addition, TARC and MDC are 
expressed in skin lesions in ATL patients. Thus, CCR4 expression should be implicated in 
the skin infiltration (Yoshie et al. 2002). On the other hand, CCR7 expression is associated 
with lymph node involvement (Hasegawa et al. 2000). OX40 is a member of the tumor 
necrosis factor family, and was reported to be expressed on ATL cells (Higashimura et al. 
1996). It was also identified as a gene associated with the adhesion of ATL cells to 
endothelial cells by a functional cloning system using a monoclonal antibody that inhibited 
the attachment of ATL cells (Imura et al. 1996). Thus, OX40 is also implicated in the cell 
adhesion and infiltration of ATL cells. Thus, ATL cells express various molecules that can 
modify their phenotypic properties, thereby modifying the clinical disease manifestation, 
and facilitating the survival of ATL cells (Matsuoka 2003). Hypercalcemia is frequently 
complicated in patients with acute ATL (more than 70% during the whole clinical course) 
www.intechopen.com
 Human T-Cell Lymphotropic Virus (HTLV-1) and Adult T-Cell Leukemia 
 
37 
(Kiyokawa et al. 1987). In hypercalcemic patients, the number of osteoclasts increases in the 
bone. RANK ligand, which is expressed on osteoblasts, and M-CSF act synergistically on 
hematopoietic precursor cells, and induce the differentiation into osteoclasts (Arai et al. 
1999). ATL cells from hypercalcemic ATL patients express RANK ligand, and induced the 
differentiation of hematopoietic stem cells into osteoclasts when ATL cells were co-cultured 
with hematopoietic stem cells (Nosaka et al. 2002). In addition, the serum level of 
parathyroid hormone-related peptide (PTH-rP) is also elevated in most of hypercalcemic 
ATL patients. PTH- rP indirectly increases the number of osteoclasts, as well as activating 
them (Watanabe et al. 1990), which is also implicated in mechanisms of hypercalcemia. 
7.3 Role of Tax in HTLV-1 induced oncogenesis 
Tax, a transactivator protein, triggers a plethora of events like cell signaling, cell cycle 
regulation and interference with checkpoint control and inhibition of DNA repair. Tax is 
expressed from a doubly spliced mRNA transcript. Although Tax shares the same mRNA 
transcript with Rex, translation of Tax is favored over Rex due to a stronger Kozak sequence. 
Tax made in the cytoplasm is translocated into the nucleus, where it binds to its response 
element and activates viral LTR-mediated transcription. (Boxus and Willems 2009). 
The tax gene plays central roles in viral gene transcription, viral replication and the 
proliferation of HTLV-1-infected cells. Tax enhances viral gene transcription from the 5'-LTR 
via interaction with cyclic AMP responsive element binding protein (CREB). Tax also interacts 
with cellular factors and activates transcriptional pathways, such as NF-κB, AP-1 and SRF 
(Yoshida 2001). For example, activation of NF-κB induces the transcription of various 
cytokines and their receptor genes, as well as anti-apoptotic genes such as bcl- xL and survivin 
(Tsukahara et al. 1999). The activation of NF-κB has been demonstrated to be critical for 
tumorigenesis both in vitro and in vivo (Mori et al. 1999). On the other hand, Tax variant 
without activation of NF-κB has also been reported to immortalize primary T-lymphocytes in 
vitro, suggesting that mechanisms of immortalization are complex. In addition to NF-κB, 
activation of other transcriptional pathways such as CREB by Tax should be implicated in the 
immortalization and leukemogenesis. Tax also interferes with the functions of p53, p16 and 
MAD1 (Ariumi et al. 2000). These interactions enable HTLV-1-infected cells to escape from 
apoptosis, and also induce genetic instability. Although inactivation of p53 function by Tax is 
reported to be mediated by p300/CBP or NF- κB activation (Pise-Masison et al. 2000), Tax can 
still repress p53's activity in spite of loss of p300/CBP binding or in cells lacking NF- κB 
activation (Miyazato et al. 2005), indicating the mechanism of p53 inactivation by Tax needs 
further investigation. Although Tax promotes the proliferation of infected cells, it is also the 
major target of cytotoxic T-lymphocytes (CTLs) in vivo. Moreover, excess expression of Tax 
protein is considered to be harmful to infected cells. Therefore, HTLV-1 has redundant 
mechanisms to suppress Tax expression. Rex binds to Rex-responsive element (RxRE) in the 
U3 and R regions of the 3'-LTR, and enhances the transport of the unspliced gag/pol and the 
singly spliced env transcripts. By this mechanism, double-spliced tax/rex mRNA decreases, 
resulting in suppressed expression of Tax (Inoue, Yoshida and Seiki 1987). Additionally, p30 
binds to tax/rex transcripts, and retains them in the nucleus. The HBZ gene is encoded by the 
complementary strand of HTLV-1, and contains a leucine zipper domain. HBZ directly 
interacts with c-Jun or JunB (Basbous et al. 2003), or enhances their degradation, resulting in 
the suppression of Tax-mediated viral transcription from the LTR. Transforming growth 
factor-ǃ (TGF-ǃ) is an inhibitory cytokine that plays important roles in development, the 
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immune system and oncogenesis. Since TGF-ǃ generally suppresses the growth of tumor cells, 
most tumor cells acquire escape mechanisms that inhibit TGF-ǃ signaling, including mutations 
in its receptor and in the Smad molecules that transduce the signal from the receptor. Tax has 
also been reported to inhibit TGF-ǃ signaling by binding to Smad2, 3 and 4 or CBP/p300 (Mori 
et al. 2001). Inhibition of TGF-ǃ signaling enables HTLV-1-infected cells to escape TGF-ǃ-
mediated growth inhibition. ATL cells have been reported to show remarkable chromosomal 
abnormalities (Sanada et al. 1986), implicated in the disease progression. Tax has been 
reported to interact with the checkpoint protein MAD1, which forms a complex with MAD2 
and controls the mitotic checkpoint. This functional hindrance of MAD1 by Tax protein causes 
chromosomal instability, suggesting the involvement of this mechanism in oncogenesis. 
Recently, Tax has been reported to interact with Cdc20 and activate Cdc20- associated 
anaphase-promoting complex, an E3 ubiquitin ligase that controls the metaphase-to-anaphase 
transition, thereby resulting in mitotic abnormalities (Liu et al. 2005). In contrast to HTLV-1, 
HTLV-2 promotes the proliferation of CD8-positive T-lymphocytes in vivo. Although it was 
first discovered in a patient with variant hairy cell leukemia, HTLV-2 is less likely to have 
oncogenic properties since there is no obvious association between HTLV-2 infections and 
cancers. Regardless of the homology of their tax sequences, the oncogenic potential of Tax1 
(HTLV-1 Tax) is more prominent than that of Tax2 (HTLV- 2 Tax). The most striking difference 
is that Tax2 lacks the binding motif at C-terminal end to PDZ domain proteins, while Tax 1 
retains it. When the PDZ domain of Tax1 is added to Tax2, the latter acquires oncogenic 
properties in the rat fibroblast cell line Rat-1, indicating that this domain is responsible for the 
transforming activity of HTLV-1. To understand the pleiotropic actions of Tax protein more 
clearly, transcriptome analyses are essential. The transcriptional changes induced by Tax 
expression have been studied using DNA microarrays, which revealed that Tax upregulated 
the expression of the mixed-lineage kinase MLK3. MLK3 is involved in NF-κB activation by 
Tax as well as NIK and MEKK1. In addition to transcriptional changes, Tax is also well known 
to interact with cellular proteins and impair or alter their functions. For example, proteomic 
analyses of Tax-associated complexes showed that Tax could interact with cellular proteins, 
including the active forms of small GTPases, such as Cdc42, RhoA and Rac1, which should be 
implicated in the migration, invasion and adhesion of T-cells, as well as in the activation of the 
Jun-kinase (JNK) pathway (figure 3) (Matsuoka 2005). 
Tax1  upregulates the expression of genes encoding cytokines, chemokines, cell surface 
ligands, and their receptors, in an NF-κB, AP-1, CREB/ATF and/or NFAT dependent 
manner. They include IL-2 receptor (IL-2R) ǂ-chain, IL-9, IL-13, IL-15/IL-15R, IL-21/IL-21R, 
IL-8, CCL2, CCL5, CCL22, CCR9, CXCR7, CD40, OX40/OX40L, and 4-1BB/4-1BBL. Among 
these, the IL-2R ǂ-chain is crucially important for T-cell immortalization by Tax, since the 
immortalized cells are dependent on IL-2 for their growth. 
ATL cells are well known to infiltrate into various organs or tissues, frequently invading 
skin or lymphoid tissues. Analysis of chemokine receptor expression revealed that CCR4 
was frequently expressed on HTLV-1-transformed cell lines and fresh ATL cells. CCR4-
positive T lymphocytes contain skin-seeking memory T cells, accounting for frequent 
infiltration of ATL cells into skin. On the other hand, expression of CCR7 was reported to be 
associated with the involvement of lymphoid tissues, and lymph node enlargement. A 
subtraction strategy between ATL cell lines and activated T cells identified I-309 as a 
secreted chemokine from ATL cells, and I-309 expression was remarkably enhanced in ATL 
cell lines. I-309 showed anti apoptotic effect via its receptor CCR8, invoking that an 
autocrine mechanism via I-309/CCR8 allowed ATL cells to survive in vivo (Matsuoka 2003). 
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Fig. 3. Pleiotropic actions of Tax. Pleiotropic actions of Tax proteins are summarized  
7.4 Inactivation of Tax expression in ATL cells  
As mentioned above, Tax expression confers advantages and disadvantages on HTLV-1-infected 
cells. Although the proliferation of infected cells is promoted by Tax expression, CTLs attack the 
Tax-expressing cells since Tax is their major target. In HTLV-1-infected cells, Rex, p30 and HBZ 
suppress Tax expression. On the other hand, loss of Tax expression is frequently observed in 
leukemic cells. Three mechanisms have been identified for inactivation of Tax expression: 1) 
genetic changes of the tax gene (non- sense mutations, deletions or insertions); 2) DNA 
methylation of the 5'-LTR; and 3) deletion of the 5'-LTR. Among fresh leukemic cells isolated 
from ATL patients, about 60% of cases do not express the tax gene transcript. Interestingly, ATL 
cells with genetic changes of the tax gene expressed its transcripts, suggesting that ATL cells do 
not silence the transcription when the tax gene is abortive. Loss of Tax expression gives ATL cells 
advantage for their survival since they can escape from CTLs (Figure 4) (Matsuoka 2005). 
Some ATL cells can proliferate without functional Tax protein, suggesting that somatic 
(genetic and epigenetic) alterations cause transcriptional or functional changes to the host 
www.intechopen.com
 T-Cell Leukemia 
 
40
genes. The mutation rate of the p53 gene in ATL cells has been reported to be 36% (4/11) 
and 30% (3/10) (Nishimura et al. 1995). The p16 gene is an inhibitor of cyclin-dependent 
kinase 4/6, and blocks the cell cycle. Deletion and aberrant methylation of the p16 gene 
has also been reported in ATL cells. In addition, genetic changes in the p27KIP1, 
RB1/p105 and RB2/p130 genes have been reported in ATL, although they are relatively 
rare: 2/42 (4.8%) for the p27KIP1 gene; 2/40 (5%) for the RB1/p105 gene; and 1/41 (2.4%) 
for the RB2/p130 gene) (Morosetti et al. 1995). The fact that higher frequencies of genetic 
changes in these tumor suppressor genes are observed among aggressive forms of ATL 
suggests that such genetic changes are implicated in disease progression. Fas antigen was 
the first identified death receptor. It transduces the death signal by binding of its ligand, 
Fas ligand (FasL). ATL cells highly express Fas antigen on their cell surface (Nagata 1999), 
and are highly susceptible to death signals mediated by agonistic antibodies to Fas 
antigen, such as CH-11. Genetic changes of Fas gene in ATL cells, which confer resistance 
to the Fas-mediated signal, have been reported (Tamiya et al. 1998). Normal activated T-
lymphocytes express FasL as well as Fas antigen. Apoptosis induced by autocrine 
mechanisms is designated activation-induced cell death (AICD) and this controls the  
 
 
Fig. 4. Natural course from the infection of HTLV-I to onset of ATL 
immune response (Krueger et al. 2003). Although ATL cells express Fas antigen, they do not 
produce FasL, thereby enabling ATL cells to escape from AICD. Attempts to isolate 
hypermethylated genes from ATL cells identified the EGR3 gene as a hypermethylated gene 
compared to PBMCs from carriers (Yasunaga et al. 2004). EGR3 is a transcriptional factor 
with a zinc finger domain, which is essential for transcription of the FasL gene. The finding 
that EGR3 gene transcription is silenced in ATL cells could account for the loss of FasL 
expression, and the escape of ATL cells from AICD. Thus, alterations of the Fas (genetic) 
and EGR3 (epigenetic) genes are examples of ATL cell evolution in vivo. Disordered DNA 
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methylation has been identified in the genome of ATL cells compared with that of PBMCs 
from carriers: hypomethylation is associated with aberrant expression of the MEL1S gene 
(Yoshida et al. 2004), while hypermethylation silences transcription of the p16 (Nosaka et al. 
2000), EGR3 and KLF4 genes as well as many others. It is reasonable to consider that other 
currently unidentified genes are involved in such alterations of the genome in ATL cells, 
and play roles in leukemogenesis. Transcriptome analyses using DNA microarrays have 
revealed transcriptional changes that are specific to ATL cells. Among 192 up-regulated 
genes, the expressions of the  tumor suppressor in lung cancer 1 (TSLC1), caveolin 1 and 
prostaglandin D2 synthase genes were increased more than 30-fold in fresh ATL cells 
compared with normal CD4+ and CD4+, CD45RO+ T-cells (Sasaki et al. 2005). TSLC1 is a 
cell adhesion molecule that acts as a tumor suppressor in lung cancer. Although TSLC1 is 
not expressed on normal T- lymphocytes, all acute ATL cells show ectopic TSLC1 
expression. Enforced expression of TSLC1 enhances both the self-aggregation and adhesion 
abilities to vascular endothelial cells in ATL cells. Thus, TSLC1 expression is implicated in 
the adhesion or infiltration of ATL cells. A retrovirus cDNA library screening from ATL 
cells, a gene with oncogenic potency was identified in NIH3T3 cells, and designated the 
Tgat gene. Ectopic expression of the Tgat gene is observed in aggressive forms of ATL, and 
in vitro experiments showed that its expression is associated with an invasive phenotype 
(Matsuoka 2005). 
7.5 Role of HBZ in HTLV-1-induced oncogenesis 
The pathogenesis of ATL involves four stages: infection, polyclonal proliferation, clinical 
latency and tumorigenesis. HTLV-1 induced ATL after a long latent period. Previous 
studies suggested the significance of the tax gene. However, Tax is not expressed in 
approximately 60% of ATL cases by three mechanisms: 1) deletion of 5' long terminal 
repeat (LTR), 2) DNA methylation of 5 LTR, and 3) genetic changes of the tax gene. Recent 
studies, demonstrated that the HTLV-1 basic leucine zipper factor (HBZ) encoded by the 
virus in an antisense orientation may play a critical role in the malignant proliferation of 
ATL cells. The expression of HBZ gene is detected in all ATL cases, and this is due to the 
usage of the promoter in the 3' LTR of HTLV-1 gene which is not inactivated in the ATL 
cells. HBZ interacts with various host factors, including c-Jun, JunB, JunD, and p65. Thus, 
HBZ modulates cellular signal pathways in addition to promoted proliferation. These 
findings indicate that HBZ is an essential viral gene for oncogenesis by HTLV-1(Boxus 
and Willems 2009).  
Short hairpin RNA mediated knockdowns of HBZ expression in both ATL and HTLV-1 
transformed cell lines reduce their proliferation. Moreover, transgenic mice expressing HBZ 
under the control of the CD4 promoter/enhancer display increased numbers of CD4-
positive T-cells in the spleen, and augmented proliferation of thymocytes after anti-CD3 
stimulation. Thus, these findings indicate that HBZ has a growth promoting activity, and 
could be involved in the malignant proliferation of ATL cells in vivo, although the precise 
molecular mechanism for these findings is still unclear. HTLV-2 also encodes a HBZ like 
protein, designated as the antisense protein of HTLV-2 (APH-2). Interestingly, unlike HBZ, 
APH-2 does not have a leucine zipper motif which is essential for various HBZ functions. 
Thus, it is important to study whether the HTLV-2 APH-2 protein has a growth promoting 
activity in T-cells like HBZ in order to understand better how these two viruses show 
distinct pathogenicities (Higuchi and Fujii 2009). 
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Both the HBZ and Tax genes are found in the genome of the simian T-cell leukemia virus 
type 1 (STLV-1), which shares a common ancestor with HTLV-1, indicating that HBZ has 
not been recently acquired; that is once the virus adapted to humans (STLV-1 and HTLV-1 
are considered to have diverged around 50 000 years ago. it did not tolerate genetic drift 
resulting in its silencing. In the HTLV-2 genome, a human retrovirus related to HTLV-1, Tax 
also exists but, surprisingly, HTLV-2 lacks the HBZ-ORF. Moreover, in contrast to HTLV-1 
and STLV-1, which both cause lymphoid malignancy in the host, no association between 
HTLV-2 infection and cancer has been yet evidenced. There has been only one reported case 
of a patient carrying HTLV-2 who developed a variant of hairy cell leukemia (Mesnard, 
Barbeau and Devaux 2006). 
8. ATL treatment: Current state and new strategies 
In spite of intensive chemotherapies, the prognosis of ATL patients has not improved. The 
median survival time of acute or lymphoma-type ATL was reported to be 13 months with the 
most intensive chemotherapy. Such a poor prognosis might be due to: 1) the resistance of 
ATL cells to anti-cancer drugs; and 2) the immunodeficient state and complicated 
opportunistic infections. One mechanism of resistance to anti-cancer drugs is the activated 
NF-κB pathway in ATL cells (Mori et al. 1999), which increases the transcription of anti-
apoptotic genes such as bcl-xL and survivin.  
A proteasome inhibitor, Bortezomib, is currently used for the treatment of multiple 
myeloma. One of its mechanisms is suppression of the NF-κB pathway by inhibiting the 
proteasomal degradation of IκB protein. Several groups have shown that Bortezomib is 
effective against ATL cells both in vitro and in vivo (Mitra-Kaushik et al. 2004). The 
sensitivity to Bortezomib is well correlated with the extent of NF-κB activation. 
Depsipeptide is a histone deacetylase inhibitor, and a clinical trial on its use in cutaneous T-
cell lymphoma has commenced. This drug also inhibits the activation of NF-κB and AP-1 in 
ATL cells, and it induces apoptosis (Mori et al. 2004).  
An alternative approach to the therapy of ATL is to target cell-surface markers on the 
malignant cells with monoclonal antibodies. Anti- CD25 (anti-Tac) monoclonal antibody, 
which was first administered to patients with ATL in the late 1980s, was reported to be 
effective in some patients, with a complete response in 2 of 19 patients and a partial 
response in 4 of 19 patients (Waldmann et al. 1993). Another antibody, anti- CD52 
monoclonal antibody (Campath-1H), is being evaluated in a phase II clinical trial by the 
National Institutes of Health (Protocol 03-C-0194). Humanized anti-CD2 antibody (MEDI-
507) has also been shown to be effective in vivo (Zhang et al. 2003). Bortezomib effect 
could be enhanced by combined use of anti-CD25 antibody (Tan and Waldmann 2002). 
During chemotherapy for ATL, chemotherapeutic agents worsens the immunodeficient 
state of ATL patients. Antibody therapy against ATL cells has advantages due to its 
decreased adverse effects.  
As described above, most ATL cells express CCR4 antigen on their surfaces, and a 
humanized antibody against CCR4 is being developed as an anti-ATL agent (Ishida et al. 
2004). Advances in the treatment of ATL were brought about by allogeneic bone marrow or 
stem cell transplantation (Borg et al. 1996; Yamada et al. 2001). Absence of graft-versus-host 
disease (GVHD) was linked with relapse of ATL, suggesting that GVHD or graft-versus-
ATL may be implicated in the clinical effects of allogeneic stem cell transplantation (Borg et 
al. 1996). Furthermore, 16 patients with ATL, who were over 50 years of age, were treated 
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with allogeneic stem cell transplantation with reduced conditioning intensity (RIST) from 
HLA-matched sibling donors (Okamura et al. 2005). Among 9 patients in whom ATL 
relapsed after transplantation, 3 achieved a second complete remission after rapid 
discontinuation of cyclosporine A. This finding strongly suggests the presence of a graft-
versus-ATL effect in these patients. In addition, Tax peptide-recognizing cells were detected 
by a tetramer assay (HLA-A2/Tax 11–19 or HLA-A24/Tax 301–309) in patients after 
allogeneic stem cell transplantation (Harashima et al. 2004). In 8 patients, the provirus 
became undetectable by real- time PCR. Among these, 2 patients who received grafts from 
HTLV-1-positive donors also became provirus-negative after RIST. Since the provirus load 
is relatively constant in HTLV-1-infected individuals (Etoh et al. 1999), this finding indicates 
an enhanced immune response against HTLV-1 after RIST, which suppresses the provirus 
load. This may account for the effectiveness of allogeneic stem cell transplantation to ATL. 
However, Tax expression is frequently lost in ATL cells as described above. Many questions 
arise, such as whether the tax gene status is correlated with the effect of allogeneic stem cell 
transplantation, and whether the effectiveness of the anti-HTLV-1 immune response is 
against leukemic cells or non-leukemic HTLV-1-infected cells. Nevertheless, these data 
suggest that potentiation of the immune response against viral proteins such as Tax may be 
an attractive way to treat ATL patients. Such strategies may enable preventive treatment of 
high-risk HTLV-1 carriers, such as those with familial ATL history, predisposing genetic 
factors to ATL, a higher provirus load, etc (Matsuoka 2005). 
The leukemic phase of ATL tends to spare the bone marrow; accentuated anemia and 
thrombocytopenia are not observed. White blood cell counts are always elevated and can be 
as high as 100,000/mm³. Heightened leukocyte counts and elevated lactate dehydrogenase 
(DHL) and calcium levels are markers of worse prognosis. Atypical lymphocytes that are 
pleomorphic and lobulated and have significant nuclear abnormalities (flower cells) are 
found in peripheral blood. If left untreated it is rapidly fatal, with death caused by 
pulmonary complications, opportunistic infections, sepsis and uncontrolled hypercalcemia. 
The chronic and indolent forms of ATL are less common, but after a number of years they 
will evolve into the acute form. Treatment of the indolent and chronic forms can be 
postponed until they evolve into the acute form; despite a less aggressive clinical course, 
prognosis for survival over the long term is poor. Some studies, with small patient samples 
and short follow-up periods, have demonstrated a satisfactory response and moderate 
toxicity using zidovudine in combination with interferon alpha, and both of these in 
combination with arsenic. In the more aggressive acute and lymphomatous forms, treatment 
should be started as early as possible using, CHOP chemotherapy regimens 
(cyclophosphamide, doxorubicin, vincristine and prednisolone).  More powerful regimens 
such as VCAP (vincristine, cyclophosphamide, doxorubicin and prednisolone) or AMP 
(doxorubicin, ranimustine and prednisolone), offer a better response and prognosis, but 
mortality is higher. Other treatment options described in the literature include allogeneic 
stem cell transplant, inhibition of the NF-kappa Beta protein and monoclonal antibodies 
(Romanelli, Caramelli and Proietti 2010). 
Regardless of the extensive progress in virology, immunology and molecular biology of 
ATL and HTLV-1, the prognosis of patients with ATL remains poor. ATL is generally 
treated with aggressive combination chemotherapy, but long-term success has been less 
than 10%. The acute form, with hypercalcemia, high LDH levels and an elevated white 
blood cell count shows a particularly poor prognosis. Although G-CSF supported 
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combination chemotherapy with eight drugs improved the survival (mean survival time 13 
months), the prognosis of aggressive ATL remains poor with deaths usually being the result 
of severe infection or hypercalcemia, often associated with drug resistance. After successful 
allogeneic bone marrow transplantation (alloBMT) for a patient with ATL was reported, 
more patients with ATL were treated with alloBMT. The low risk of relapse in cases with 
graftversus-host disease, suggested that graft-versus-leukemia was effective against ATL 
cells. CTLs attack ATL cells via Fas ligand, perforin or granzyme. These results are 
consistent with the finding that ATL cells are highly susceptible to the signal via Fas antigen. 
Thus, the signal through Fas antigen might be a good target in therapy against ATL 
(Matsuoka 2003). 
In a phase II study, combination of zidovudine and interferon-alpha presented promising 
results. Chronic ATL has a relatively better out-come, but poor long-term survival is noted 
when patients are managed with a watchful-waiting policy or with chemotherapy. In ATL cell 
lines, arsenic trioxide shuts off constitutive NF-B activation and potentiates interferon-alpha 
apoptotic effects through proteasomal degradation of Tax. In conclusion, treatment of chronic 
ATL with arsenic, interferon- alpha, and zidovudine is feasible and exhibits an impressive 
response rate with moderate toxicity. Viral replication (AZT) and Tax degradation (As/IFN) 
may eradicate the disease through this treatment. These clinical results strengthen the concept 
of oncogene-targeted cancer therapy (Kchour et al. 2009). 
Key Words: HTLV-1, ATL, Leukemia, Molecular pathogenesis, Diagnosis, Novel 
treatements, Oncogenesis, Mutation, Arsenic, Interferon-alpha, Zidovudine  
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